


# **Clinical pharmacology of cardiovascular system diseases**

---

**medication: antiarrhythmic,  
antianginal,  
drugs used in cardiac failure.**

Lilia Podgurschi- PhD, university associated professor

# Transmembranar potential evolution (cell electrograma)



# Classification of antiarrhythmic drug (according to Williams with modification)

**Class I: Na channel blockers (and K channels to some extent)**

**class I A** (time of restoration the Na channel block from 0,3 — till- 1,5 sec.): **quinidine, procainamide, disopyramide, imipramine, ajmaline, lorajmaline, prajmalin**

**MA:** they inhibit  $\text{Na}^+$  influx ( Ph 0 and 4 );

**Effects:** - ↓ diminish the polarization;

- they prolong repolarization and ERP,
- ↓ automatism, excitability, conductivity, contractility,
- ↑ cardiac rate - adrenergic properties (↓AP);
- parasympatholytic properties;

**Indications:** Useful for treatment of ventricular and atrial tachyarrhythmia

**Contraindications:** arrhythmias caused by digitalis, AV block, hyperkalemia, in children.

**Pharmacokinetics:** Good absorption from intestine and binding with albumins in 90%. **T<sub>1/2</sub>**- procainamide 2-3 hours; disopyramide 6 h, ajmaline-8 minutes. Elimination by urine.

**Subclass I B** (time of restoration the Na<sup>+</sup>channel block < 0,3 sec.): **lidocaine, tocainid, mexiletine, phenytoin**

**MA:** they inhibit Ca<sup>2+</sup> and Na<sup>+</sup> influx (ph 4)

**Eff:** —↓ duration of action potential, do not influence ERP, —  
↓ automatism; ↑ cardiac rate.

**Indic:** ventricular arrhythmias, myocardial infarction,  
intoxication with digitals;

**Contraind:** cardiac block, liver failure, convulsion

**Subclass I C** (time of restoration of the blocked Na<sup>+</sup>channel > 1,5 sec):  
**flecainide, encainide, lorcainide, moracizine, propafenone.**

**Eff:** the same like IA.

**Side effects:** proarrhythmic effect therefore are indicated only in  
ventricular tachyarrhythmia resistant to other drugs.

**Contraind:** AV block, myocardial infarction.

## **Class II: beta-adrenoblockers:**

**n/selective SIA -:** propranolol, nadolol, sotalol, timolol;

SIA +: pindolol, oxprenolol, alprenolol

**selective SIA- :** bisoprolol, esmolol, betaxolol, atenolol,  
metoprolol, talynolol, nebivolol\*;

SIA +: acebutolol\*, practolol;

They reduce sodium and calcium currents (ph 3-4);

↓ automatism, excitability, conductibility, contractility,  
↓ cardiac rate, ↓ cAMP;

**Ind:** supraventricular tachyarrhythmia, especially which  
are produced by physical effort; WPW syndrom.

## Class III: prolong refractory period

---

(↓K efflux (f3): amiodarone, ibutilide, dofetilide, sotalol, bretilium.

- bretylium is used as a "chemical defibrillator" when arrhythmia is resistant to standard methods.

**Ind:** amiodarone in supraventricular and ventricular tachyarrhythmia, WPW syndrom;

- sotalol in supraventricular tachyarrhythmia.

## **Class IV. Calcium channel blockers:**

Verapamil, galopamil, diltiazem, bepridil

---

**MA:** block slow responses of A-V conduction (ph 2,3-4) → ↑ERP

**Effects:** ↓automatism, excitability, conductivity,  
contractility, ↓cardiac rate;

Highly effective in treatment of supraventricular and ventricular tachyarrhythmias.

## **Class V. different groups:**

- **cardiac glycosides,**
- **adenozine,**
- **potassium drugs,**
- **magnezium sulfate.**

# Adenosine

Is a normal component of the body, but it is given in high doses (6-12 mg) i/v, which reduces calcium current.





# Bradycardia

---

- **-M-cholinoblockers**
- **Alfa-adrenoblockers**
- **Calcium channel blockers ( dihydropiridines)**
- **Direct vasodilators**



# Drugs Used in Heart Failure

---

# Classification according to the pathogenic mechanism of action

---

- I. Inotropic positive drugs.**
- II. Drugs that ↓ Preload:**
- III. Drugs that ↓ Afterload:**
- IV. Drugs that ↓ Blood volume - Diuretics.**

# Inotropic positive drugs.

- **Inhibitors of sodium pump** ( $\text{Na}^+ \text{K}^+ \text{-ATPase}$ ) – *cardiac glycosides* (strophanthin, corglicon, digoxine, digitoxine).
- **Cardiostimulators:**  
*dopamino- and beta – adrenomimetics*: dopamine, dobutamine, izoprenaline, dopexamine, epinephrine.
- **Phosphodiesterase inhibitors :**  
amrinone, milrinone, enoximon and methylxantines: aminophylline, theophylline.
- The drugs that  $\uparrow$  **heart sensitivity to calcium-**levosimendan.

## **II. Drugs that ↓ preload**

**Venodilatators: nitroglycerin, izosorbid DN and MN;**  
**Diuretics**

## **III. Drugs that ↓ afterload:**

**Arteriodilatators:** hidralazine, minoxidil, diazoxid, verapamil, diltiazem, nifedipine, amlodipine, felodipine, nicardipine, nisoldipine, isradipine etc.

## **Drugs that ↓ preload and afterload:**

**Arterio- and venodilatators:**

- **vasodilators:** sodium nitroprusside, bendazol,  $\text{Mg}_2\text{SO}_4$
- Alfa-AB: prazosin, doxazosin, phentholamine,
- ACEI: captopril, enalapril, lizinopril, ramipril, quinalapril,
- ATRI: losartan, valsartan, irbesartan, etc.

# Cardiac glycosides (CG)

---

**Cardiac glycosides** – of vegetal origine or semisynthetics derivates capable to intensify the contractility (force and speed contraction) of miocard in cardiac faluire with pump defficit.

- Classification of cardiac glycosides according to the:
  - - speed of effect development;
  - - duration of action;
  - - cumulative capacity;
  - - way of administration;
  - - indications for administration.

## I Inotrop - positive effect (CG)

---

- They ↑ the force and speed of contraction → shorten the contraction duration and ventricular ejection, ↑ time of the diastolic filling, the heart empties better, pressure and the diastolic volume ↓. These all ↑ myocardial tone, and contribute to the ↓ heart diameter and necessity in oxygen.

## II. Chronotrop - negativ effect

---

- manifested through bradycardia and is parasymphathethic origine. Effect may be diminuated by atropine and is absent in patients with heart transplant. Clinic situation with  $\uparrow$  of the symphathethic tonus and reduction of parasymphathethic (fever, thyriotoxicozes) respond slowly to chronotrop - negativ action of digitalics. In this case it is necessary to associate  $\beta$ -adrenoblockers.



### III. dromotrop - negative effect

slowness of conductivity through AV junction. Therefore action potential develops more slowly, and have more duration, refractory period became longer due to ↑ vagale influence. Dromotrop - negative effect is used in: atrial flutter, atrial fibrillation; cardiac failure with tachiarithmia, supraventricular paroxistic tachicardia.

- In AV blocade, WPW syndrom dromotrop negativ action – is unfavourable. In late AV blocade conducting is slower, that can provoke Morgan-Adams-Stokes attack. In WPW syndrom, in AV blocade, CG provoke transmission impulse through accessory ways of conductivity, producing paroxistic tachicardia.



## IV. Batmotrop positive effect

---

is undesirable and provokes ectopic automatism. In atrium therapeutic dose provokes ↓duration of action potential and effective refractory period, contributes to ↑ of atrial excitement. This indirect action, is mediated by acethylcholin, explains why digitals can ↑ atrial fibrilation or fluter.

## Influence on heart and haemodynamics (CG)

<b>Normally</b>	<b>heart</b>	<b>cardiac</b>	<b>failure</b>
<b>Effects</b>	<b>haemodynamic modifications</b>	<b>Effects</b>	<b>haemodynamic modifications</b>
<ul style="list-style-type: none"> <li>- Stimulate cardiac contraction;</li> <li>-arterioloconstriction;</li> <li>-venoconstriction systemic;</li> <li>-venoconstriction in liver;</li> <li>-Vagus stimulation.</li> </ul>	<ul style="list-style-type: none"> <li>-Do not influence cardiac output;</li> <li>-↑ AP;</li> <li>- venous retention;</li> <li>- Liver retention</li> <li>- bradycardia.</li> </ul>	<ul style="list-style-type: none"> <li>Stimulate cardiac contraction;</li> <li>-arteriodilatations</li> <li>-venodilatation; systemic;</li> <li>Venodilatation in liver;</li> <li>↓sympathetic tonus</li> </ul>	<ul style="list-style-type: none"> <li>-↑expressively cardiac output;</li> <li>-↓AP;</li> <li>-↓systemic venous pressure;</li> <li>-↓ expressively <u>of</u> venous retention;</li> <li>-stoped tachicardia;</li> </ul>

# Digitalization can be achieved:

---

- rapidly (1-2 days) – preferable in atrial fibrillation, paroxistic tachicardia, acute pulmonary edema;
- intermediately (3-5 days)-in situation less emergency of cardiac failure;
- Slowly (5-7 days);



# **Plan of digitalization.**

---

## Rapidly (in acute cardiac failure).

---

- Strophantin i/v.
- Initial 0,125 mg in 6-10 minutes;
- After that by 0,125 mg with interval of 30-40 minutes;
- But not more than 1mg /24 hours.

## Intermediate (in subacute cardiac failure).

---

- Digoxin can be indicated - 3 days:
- i/v saturated dose **0,8-2,2 mg**
- Inward 1- 2,5 mg                      Ex:1000mcg
- I day - 50 %              40%              500mcg
- II day – 25 %              30%              250mcg+100mcg=350 /750mcg
- III day – 25%              30%              250mcg+150mcg=400/1000mcg
- 4 day- 200mcg/1000mcg

Every day 20-30 % are eliminated from body.

slow

## **Digoxin**

---

- internal in I-V days by 0,125 mg- 0,75 mg/day,  
in a VI-VII days by 0,25- 0,5 mg/day.

## **Digitoxin**

I day - 0,5 mg;

II-III day - 0,4 mg;

IV-V day - 0,3 mg;

VI-VII day –0,2 mg.

digoxin digitalization is used more often through slow parenteral and enteral method.



## **Efficacy and inoffensivity criteria of CG**

### ○ Manifested through:

---

- 1) Discontinuity of arithmia;
- 2) pulse deficit removal is considered as beneficial effect;
- 3) Reduced cardiac frequency till 60-70 /minut; but bradycardia or AV blockage are considered overdoses,
- 4) Nocturnal tahipnoea is diminished;
- 5) ↑ diuresis and diminished peripheral edema and weight (not more then 0,5-1 kg/day);
- 6) Disappearance of the wet wheeze in lungs;
- 7) ↓ liver size.



# ECG modifications:

---

- 1) interval PQ (not more than 0,2 sec) indicates about AV conductivity;
- 2) Evolution wave T shows the intensity of coronary flux.
- 3) Amplitude wave R and duration of the complex QRS demonstrate inotropic - positive effect (systolic action).

# Peculiarities of CG action

In older patients are recommended smaller doses  $\approx$  50 % due to deficitary renal function and reduction of muscular weight,

- In children miocard is less sensible at digitalics, digoxine  $T_{0,5}$  is shorter than in adults, therefore it is necessary to administrate bigger doses (calculated on kg weight);
- premature newborn, have miocardic sensitivity more expressive and  $T_{0,5}$  longer; doses must be smaller;
- diarrhoea, malabsorbtion syndrom, edematous intestinal mucosa diminish the absorbtion of CG;
- kidney failure cumulates digoxine and it is necessary to ↓ doses;

# Peculiarities of CG action

---

- hypokaliemia and hypomagneziemia are provoked by abuse of diuretics, corticosteroids and contribute to arrhythmia even small doses of digitals.
- hyperkaliemia provokes digitalic blockage;
- In patients with weight < 60 kg GC doses must be diminished by 1/4-1/3;
- in obesity the doses must not ↑ according to the weight (GC are cumulated in muscles and less in fats).

## Interaction of the digoxine with other drugs

etacrinic acid	Hypokaliemie, hypomagneziemia
2. amiodarone	↑ D concentration by 69 % in blood
3. β-AB, chinidine	↑ D concentration by 100 %
4. Eritromicine	↑ D concentration by 116 %
5.Furosemide, glucoze	↑ D concentration by 60 %
6. Nifedipine	↑ D concentration by 45%
7.Sympathomimetics	Arithmia
8. Spironolactone	↓ excretion by urine
9. Tetraciline	↑ D concentration by 100 %
10. Diuretics tiazide	Toxicity, bigiminia
11.Verapamil	↑ D concentration by 41%

## B. ↓ digoxin effects

The drug	Causes
1. Alcohol, antacids	↓ GI absorption
2. Colestiramine	↓ GI absorption, ↓ $T_{1/2}$ by 50%
3. Sodium nitroprusside	↑ excretion by urine
4. Metoclopramide	↓ GI absorption
	↓ GI absorption
5. Neomycin	↓ GI absorption
6. Prednisone	↑ metabolism

## Intoxication with CG

- Intoxication with CG can be manifested at 20-35% of patients.

The causes can be:

- big doses;
- association with other drugs, which increases cardiac effects (simpatomimetics, calcium);
- hypokaliemia;
- carbohydrates diet;
- treatment prolonged with saluretics and glucocorticoids;
- hypomagneziemia;
- liver failure;
- kidney failure.

# Clinic Symptoms of intoxication with CG

---

cardio-vascular disturbance: atrial or ventricular extrasystolia, bradycardia till complete A-V blockage, ventricular fibrillation, tachiaritmia, ↓ contractility, ↓ coronary flux.

- neurological disturbance : headache, dizziness, weakness, anxiety, depression, halucination, excitement;
- oftalmics disturbance : cromatics colours perception (especially yellow or green).
- digestive disturbance : nausea, anorexia, vomiting, hypersalivation, diarrhoe, pain in abdomen.
- rarely: allergic reaction, thrombocitopenia, ginecomastia.



# Treatment of intoxication.

---

## **It is recommended:**

- R that ↓ CG gastrointestinal absorption : activated charcoal, carbosem, Medicas E, tanin, colestiramina,  $Mg_2SO_4$ ;
- R that bind CG: unitiol (contains SH group, which reactivate  $Na^+$ ,  $K^+$ , ATP-ase);
- Specific antibodies to digoxin (digibind);
- R that bind  $Ca^{++}$ : etilendiamintetraacetate( EDTA), sodium cytrate;
- R that ↓ hypokaliemia: potasium chlorate, panangin, asparcam;
- Abolition of arithmia: potasium drugs, fenitoin, lidocaine, propranolol, verapamil, atropine.

# Antianginal drugs

---

- Drugs ↓ heart necessity in oxygen:  
***β-adrenoblockers, bradycardics R (ivabadrine):***
- Drugs ↓ heart necessity O<sub>2</sub> and ↑ delivery O<sub>2</sub> to heart:  
***calcium channel blockers, potassium channel activators, nitrates, amiodarone.***
- Drugs ↑ delivery oxygen to heart (Coronarodilators):
  - a) ***miotropics - Dipyridamol,***
  - b) ***with reflectory action - Validol***
- Cardioprotectives – ***Trimetazidine, mildoniu***

# Mechanism of action

---

## ○ NITROGLYCERIN<sub>e</sub>

### ○ Venodilation



↓ preload



↓ heart volume



↓ heart necessity in oxygen

### Arteroidilation



↓ afterload



↓ AP

# Side effects

## **Earlier:**


---

- headache, weakness;
- skin congestion (more often in the upper half of the body);
- tachycardia, palpitation;
- arterial orthostatic hypotension;
- methemoglobinemia

# Later *Tardive.*

---

- **Tolerance:**
- initial, ↓ effect can be caused by activation of compensatory mechanisms of vasodilation (activation of sympathetic catecholaminergic system and renin-angiotensin-aldosterone system);
- - later, are exhausted sulfhydryl groups →  
↓ metabolic forming NO and thiocyanates;



---

It can be prevented, using combination intermittently the nitrates retard form to provide antiischemic protection 12-16 hours, other 12 hours without the nitrate, using other remedies like  $\beta$ -adrenoblocker or Calcium channel blocker.

## *Classification CCB according to the generations*

*(T. Toko-Oka, W. G. Nayer, 1995, with modification)*

Generation I	Generation II A	Generation II B	Generation III
<u>Fenilalchilamins</u> Verapamil			
<u>Benzothiazepins</u> Diltiazem			
<u>Dihidropiridins</u> Nifedipină	Nifedipină SR/ GITS Felodipină ER Nicardipină SR	Benididipină, Felodipină, Nimodipină, Nicardipină, Nisoldipină, Isradipină, Nitrendipină, Nilvadipină.	Amlodipină Lacidipină

# Mecanism of action

## **Fenilalchilamines:**

---

**↓ heart contractility and heart frequency → ↓ heart neccesity in oxygen.**

## **Benzothiazepines:**

- ↓ heart contractility and frequency → ↓ neccesity in oxygen;
- - artereodilation → ↓ afterload → ↓ neccesity of heart in oxigen;
- - improving coronary circulation → ↑ aproving the heart with oxygen, especially the ischemical zone.



# Dihydropiridines:

---

- arterydilation  $\rightarrow$   $\downarrow$  afterload  $\rightarrow$   $\downarrow$  heart neccesity in oxygen
- Improving the coronarian flux  $\rightarrow$   $\uparrow$  heart delivery with oxygen, especially the ischemical zone.

# Effects

---

- antihypertensive (hypotensive);
- cardioprotective, nephroprotective;
- antiarrhythmic;
- antiplatelets;
- bronchodilator;
- antiatherogenic:
  - to stop  $\text{Ca}^{2+}$  cumulation and lipides from arterial wall,
  - decrease collagen syntheses.

## Potassium channel activators as antianginals

---

- Opening potassium channel  $\rightarrow$   $\uparrow$  efflux ions  $K^+$  from cell  $\rightarrow$  hyperpolarization of membrane  $\rightarrow$  don't open  $Ca^{2+}$  dependent channel  $\rightarrow$   $\downarrow$   $Ca$  concentration intracellular  $\rightarrow$   $\downarrow$  muscle tonus;
- - nicorandil  $\rightarrow$   $\uparrow$  forming the NO  $\rightarrow$  effect similar for nitrates.

## Amiodarone as antianginal

- uncompetitiv blocked  $\beta$ 1-receptors from heart  $\rightarrow$   $\downarrow$  heart frequency and contractility  $\rightarrow$   $\downarrow$  necessity in oxygen;
- blocked  $\alpha$ -receptors from vassel  $\rightarrow$   $\downarrow$  afterload  $\rightarrow$   $\downarrow$  necessity in oxygen;
  - blocked  $\alpha$ -receptors from coronary vessel  $\rightarrow$   $\uparrow$  coronary flux  $\rightarrow$   $\uparrow$  heart delivery in oxygen;
  - antianginal effect is manifested throught decreasing the number of anginal acces and  $\uparrow$  tolerance to fizical loading.

# Commonly used combinations of antianginal drugs

---

Rational: to diminish dosages of individual agents to reduce side effects, while keeping therapeutic effectiveness;

- b. Beta-blocker plus nitrate against exertional angina: interruption of sympathetic reflexes that compensate for vasodilation, reduced blood pressure, and lower cardiac output
- c. Nifedipine and beta-adrenergic blocker
- d. Nitrates and calcium channel blocker (vasospastic and exertional angina)

---

***Thank you all***

